Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents (Note 5)	$ 2,694.5	$ 2,067.0
Short-term investments (Note 5)	134.6	144.8
Accounts receivable, net of allowances of $13.8 (2023) and $16.0 (2022)	7,516.1	6,896.0
Other receivables	1,655.3	1,662.9
Inventories	4,798.7	4,309.7
Prepaid expenses and other current assets	4,532.4	2,954.1
Total current assets	21,331.6	18,034.5
Investments (Note 5)	2,745.1	2,901.8
Goodwill	4,078.9	4,073.0
Other intangibles, net	6,903.5	7,206.6
Deferred tax assets	3,805.9	2,792.9
Property and equipment, net of accumulated depreciation of $10,631.6 (2023) and $10,233.4 (2022)	11,277.4	10,144.0
Other noncurrent assets	4,671.6	4,337.0
Total assets	54,814.0	49,489.8
Current Liabilities
Short-term borrowings and current maturities of long-term debt	661.6	1,501.1
Accounts payable	2,474.2	1,930.6
Employee compensation	867.7	1,059.8
Sales rebates and discounts	10,389.9	8,784.1
Dividends payable	1,016.2	1,017.2
Income taxes payable	1,233.8	475.1
Other current liabilities	2,271.6	2,370.3
Total current liabilities	18,915.0	17,138.2
Other Liabilities
Long-term debt	18,158.4	14,737.5
Accrued retirement benefits (Note 7)	1,308.8	1,305.1
Long-term income taxes payable	3,330.7	3,709.6
Other noncurrent liabilities	1,951.8	1,824.0
Total other liabilities	24,749.7	21,576.2
Commitments and Contingencies (Note 8)
Eli Lilly and Company Shareholders' Equity
Common stock	593.6	594.1
Additional paid-in capital	6,948.6	6,921.4
Retained earnings	10,368.5	10,042.6
Employee benefit trust	(3,013.2)	(3,013.2)
Accumulated other comprehensive loss (Note 9)	(3,788.7)	(3,844.6)
Cost of common stock in treasury	(45.0)	(50.5)
Total Eli Lilly and Company shareholders' equity	11,063.8	10,649.8
Noncontrolling interests	85.5	125.6
Total equity	11,149.3	10,775.4
Total liabilities and equity	$ 54,814.0	$ 49,489.8